All News

The FDA has approved a human papillomavirus vaccine (Gardasil) for use in boys and young men.

Final results from a large, 4-year study shows that combination treatment with dutasteride (Avodart) and tamsulosin (Flomax) reduces the risk of acute urinary retention or BPH-related surgery and reduces the risk of BPH clinical progression more than tamsulosin alone.

Stem and regenerative cells from autologous fat tissue can be safely used to treat stress urinary incontinence, according to findings from a small study by Japanese researchers.

Minimally invasive procedures for radical prostatectomy, including robotic assistance, may shorten hospital stays and decrease respiratory and surgical complications, but may also result in an increased rate of certain complications, including incontinence and erectile dysfunction, according to findings from a recent study.

Leading U.S. urologists have been appointed to new posts at the University of Minnesota, Minneapolis; NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York; and Rhode Island Hospital/The Miriam Hospital, Providence.

An investigational formulation of testosterone solution 2% (Axiron) is effective in men with hypogonadism, according to recently released results of a phase III trial examining 155 men across six countries and 26 sites.

Men largely make decisions about prostate cancer screening based on conversations with their clinicians, but these discussions often do not include information about both the risks and benefits of testing, a study in Archives of Internal Medicine (2009; 169:1611-8) suggests.

Hormone therapy used for the treatment of men with advanced prostate cancer is associated with an increased risk of developing various heart problems, according to findings from a study being called the largest and most comprehensive to examine this issue.

Enforcement of the Federal Trade Commission's "Red Flags Rule" begins Nov. 1. Is your practice ready?

Here are some tips for developing an incentive plan that will keep your medical staff motivated.

Adding physician videos to a Web site is a unique and easy way to not only make your practice stand out, but also provide another avenue for patient education.

Single-port laparoscopic surgery could be the next big advancement in laparoscopic surgery.

Because, as one urologist observed, "we spend more time with our partners than with our families," the importance of finding qualified urologists whose professional and personal styles are compatible with the colleagues in the practice is paramount.

The Centers for Medicare & Medicaid Services is in the process of finalizing proposed Medicare policies and payment rate changes for health care providers that would have significant impact on many urology practices.

Cryoablation of small renal masses yields similar survival rates with a laparoscopic or percutaneous approach, but the options involve tradeoffs of disease control versus convenience and cost.

Last year's market selloff led many investors to take advantage of some unique tax planning opportunities.

Outcomes of studies reviewing patients who have undergone placement of a coil-based metallic ureteral stent indicate it is a viable alternative for management of benign and malignant upper urinary tract obstruction.

Laparoscopic and robotic pyeloplasty appear to be equally effective in correcting utereropelvic junction obstruction.

In heavily pretreated men with castration-resistant prostate cancer, a specific and irreversible inhibitor of the enzyme CYP17 promotes declines in levels of PSA and the number of circulating tumor cells and an improvement in performance status.

The temperature spread of blood vessel-sealing devices is limited during radical prostatectomy, meaning that these devices can be used safely for nerve-sparing procedures, provided that the right precautions are taken.

Sandra Vassos, MPH, executive director of the AUAF, discusses the foundation's increasingly visible initiatives.

Researchers developing a degradable ureteral stent report progress with their project that supports moving forward into clinical trials.

Stone burden, a non-modifiable factor, was the only independent predictor associated with cost for PCNL.

Several approaches have been taken to attenuate lower urinary tract symptoms and improve quality of life in the stented patient.

"The minute you start letting patients go down that path, where they're using e-mail to communicate, they'll take advantage of it."

Two monoclonal antibodies have demonstrated antitumor activity in clinical trials of men with castrate-resistant prostate cancer.

Percutaneous nephrolithotomy, with or without a tube, offers a high success rate in treating small or asymptomatic lower-pole stones.